INTRODUCTION
With the benefit of hindsight, the major reason for the 20-year gestation period between the initial discovery of EPF (1, 2) and its isolation and definitive characterization (3) can be seen to be the nature of the dose-response of the bioassay for EPF, the rosette inhibition test. This has been discussed in some detail previously (3) (4) (5) . In essence, it is failure to appreciate three elements of the assay which has resulted in conflicting claims about the nature of EPF, as well as the apparently irreconcilable outcomes from a variety of attempts at purification of the active factor (see Ref. 6 for analysis of these different outcomes).
The three essential points are
(1) the dose-response curve is bell-shaped, with high as well as low concentrations giving negative results; (2) substances are present in various biological samples which, while themselves inactive in the bioassay, can modify the response by shifting the entire dose-response curve by several orders of magnitude; and (3) the bioassay is sensitive to the molecular level.
Points 1 and 2 in combination mean that when complex biological mixtures are fractionated, the most active fractions can be easily overlooked. The result is the selection of fractions containing either protein with very low activity, which is thus at best of peripheral interest, or predominantly inactive protein and small amounts of EPF. It is only by testing samples over a very wide range of dilutions that the bioassay can be applied semiquantitatively and the most active fractions selected at each fractionation step.
Point 3 means that only trace amounts of EPF need be present for an apparently pure preparation of an inactive protein to be mistakenly identified as "EPF."
ISOLATION AND CHARACTERIZATION OF EPF
These insights into the bioassay were gained from attempts in our laboratory to isolate the EPFactive agent from a wide variety of biological source materials (although point 3 was not fully appreciated until complete purification was achieved). Even with this knowledge, the final breakthrough did not occur until our studies on the biology of EPF (reviewed in Ref. 6 ) identified human blood platelets as a relatively rich source material.
To ensure that the platelet-derived material was truly representative of EPF, we fractionated, in parallel, all major classes of source materials with activity in the rosette inhibition test, including the archetypal source, pregnancy serum (3,7). The identical biochemical and immunologic behavior displayed by the active agents from all materials indicated that we were dealing with a single substance, or closely related family of substances, acting in diverse biological situations. However the only sources providing sufficient product to study at the protein, as opposed to the activity, level were regenerating rat liver (7) and human platelets (3), yielding, respectively, 5 ug per 40 g of tissue and 45 ug per 300 U (platelets from approximately 150 Liters of blood), with a purification factor of approximately 105-fold.
Structural studies were conducted on the more abundant platelet-derived material. Analysis by SDS-PAGE and mass spectrometry established the high degree of homogeneity of the preparation. After proteolytic cleavage, the amino acid sequence of approximately 70% of the molecule was determined. With a single exception, this was identical to the sequence of rat chaperonin 10 [cpn10 (8) ] and the determined mass was consistent with this being the only difference. We have since isolated a cDNA for human EPF/cpn10 (9) confirming a single residue difference between the rat and the human molecules.
These results were surprising in light of known properties of chaperonins. cpn10 and its functional associate, cpn60, are heat shock proteins which function within eukaryote mitochondria and plastids as molecular chaperones (10, 11) . The Escherichia coli homologues are known as groES and groEL, respectively (12) . Nevertheless, further studies (3) with platelet-derived EPF, rat mitochondrial cpn 10, and groEL established that the structural similarities between EPF and cpn10 extend to functional identity. groES, however, exhibited no activity in the rosette inhibition test. Thus it appears that the EPF activity of cpn10 is a property only of the eukaryotic molecule. The studies also established unequivocally that a cpn10-like molecule is the only source of EPF activity in pregnancy serum. Furthermore, both polycional and monoclonal anti-EPF antibodies, used as neutralizing agents in previous studies from this laboratory (13) (14) (15) (16) (17) , were shown specifically to recognize cpn10 (7) .
The final assurance that we had indeed isolated EPF came with the preparation and testing of recombinant protein, as well as antibodies to synthetic peptides corresponding to different parts of the EPF/cpn10 amino acid sequence (18, 19 ; Somodevilla-Torres et a/., submitted). Both the recombinant protein and a chemically synthesized form of the molecule prepared very recently (20) are fully active in the rosette inhibition test and this activity is neutralized by the anti-EPF antibodies used in our previous biological studies. Conversely, the EPF activity of pregnancy serum is completely neutralized by affinity-purified, monospecific, polycional antibodies to short synthetic peptides, corresponding to residues 1-11 (anti-N) and 34-44 (anti-l) of rat and human EPF/cpn10.
ROLE OF EPF IN PREGNANCY
In vivo and in vitro studies, with the first-generation anti-EPF antibodies discussed above, established that EPF is essential for normal embryonic development and successful establishment of pregnancy. During the pre-and periimplantation stage, EPF is important both for first cleavage (15) and at implantation (17) . In the former case, the effect on the embryo appears to be indirect (? paracrine), but by the stage of blastocyst development, EPF acts in an autocrine fashion. Mouse embryos cultured in the presence of anti-EPF antibodies displayed normal blastocyst development, but trophoblast outgrowth was completely inhibited in almost half of the embryos, compared with those cultured with control antibody (17) .
The second-generation anti-EPF/cpn10-derived peptide antibodies discussed above have been used in similar passive immunization studies. Pregnant mice were treated, separately, with anti-N and anti-l on days 1 and 2 of pregnancy and the effect was determined on day 7 (18, 19) . As shown in our previous studies, this treatment disrupts pregnancy. The number of implantation sites per mouse was significantly reduced compared with the number expected from the corpora lutea count. The effect was embryo related because the corpora lutea count did not differ in animals treated with anti-EPF/cpn10 versus control antibodies. Now that we have prepared recombinant and synthetic EPF, we have begun to examine the direct effect of EPF on the embryo. Collaborative studies with Drs. Hill and Brenneman at the NICHD, NIH, have established that EPF appears to be an endogenous growth regulator of the early postimplantation embryo (Lee et a/., in preparation). Treatment of whole cultured E9.5 mouse embryos with exogenous EPF stimulates growth; this effect is overcome by simultaneous addition of anti-EPF antibody (anti-N), while anti-EPF alone has a growth inhibitory effect.
Results for pre-and periimplantation-stage embryos are still very preliminary. Using a Texas red-labeled synthetic EPF preparation, we have demonstrated a specific binding pattern consistent with localization of exogenous ligand to blastocyst cell membranes (Kaye et al., unpublished). Furthermore, immunohistochemical examination of mouse blastocysts with anti-EPF/cpn10 antibodies reveals extremely dense staining in the trophectoderm but little in the inner cell mass, a pattern consistent with protein secretion. Parallel immunoblots of blastocyst lysate show that the antibody recognition pattern is specific because only a single band of the correct size is evident (20) .
FOR THE FUTURE
On the question of conflicting claims about the nature of EPF, our laboratory has established, unequivocally, the identity of the serum factor responsible for activity in the rosette inhibition test. In this respect, we are aware of only one outstanding issue. Thioredoxin, itself inactive in the rosette inhibition test and therefore not EPF, appears to be a modifier of the response of EPF in this assay (22). This has been established by a series of in vitro studies, the interpretation of at least some of which might be disputed. Nevertheless, setting aside such minutiae, these studies raise the possibility that thioredoxin could be a natural regulator of EPF. Now that pure EPF protein is available, this proposition can be tested.
As for the biological role of EPF, we are continuing the types of investigations briefly sketched above. We have established an essential role for EPF in situations involving very rapid cell growth (embryonic, neoplastic and normal regenerative) and have confirmed that EPF is immunosuppressive, something first surmised from its action in the rosette inhibition test. In addition, we are investigating the genetic and regulatory mechanisms leading to the differential localization and activity of EPF and cpn 10. We have discovered that EPF and cpn10 are members of a large, evolutionarily conserved gene family, which, in the human genome, is localized on nine different chromosomal arms (9) . A number of transcripts are present in mammalian cells and sequencing has established that several genes are involved (unpublished).
We have identified the developing mouse as an appropriate model in which to characterize expression and regulation of the EPF gene. This in turn will provide us with the necessary tools to subject the gene to the ultimate functional test in gene knockout and overexpression models in vivo.
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